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A B S T R A C T
Vitamin K deﬁciency within neonates can result in vitamin K deﬁciency bleeding. Ensuring that newborns re-
ceive vitamin K is particularly critical in places where access to health care and blood products and transfusions
is limited. The World Health Organization recommends that newborns receive a 1mg intramuscular injection of
vitamin K at birth. Evidence from multiple surveillance studies shows that the introduction of vitamin K pro-
phylaxis reduces the incidence of vitamin K deﬁciency bleeding. Despite these recommendations, coverage of
vitamin K prophylactic treatment in low-resource settings is limited.
An intramuscular injection is the most common method of vitamin K administration in neonates. In low- and
middle-income countries, needle sharing may occur, which may result in the spread of bloodborne diseases. The
objective of our study was to investigate the manufacture of microneedles for the delivery of vitamin K.
Following microneedle fabrication, we performed insertion studies to assess the microneedle’s mechanical
properties. Results indicate that vitamin K in a microneedle array was successfully delivered in vitro across
neonatal porcine skin with 1.80 ± 0.08mg delivered over 24 h. Therefore, this initial study shows that mi-
croneedles do have the potential to prevent vitamin K deﬁciency bleeding. Future work will assess delivery of
vitamin K in microneedle array in vivo.
1. Introduction
Vitamin K, a fat-soluble vitamin, functions as a cofactor for gamma-
carboxylase enzymes within the liver (Ozdemir et al., 2012). This role
enables posttranslational conversion of inactive hepatic precursors II,
VII, IX, and X into active clotting factors through gamma-carboxylation
of glutamic acid residues (Shearer, 1995; Smith et al., 2015). Hepato-
cyte secretion into the blood signiﬁes the end stage of carboxylation,
enabling regulation of the clotting cascade (Smith, et al., 2015).
Due to its fat-soluble properties, vitamin K is largely stored in the
liver of adults and children. Only a small amount (approximately 1 µg/
kg/day) is required in the diet. Sources of vitamin K include green leafy
vegetables, vegetable oils, and cereal grains (Shearer, 1995). However,
within neonates, a relatively small amount of vitamin K is found in the
liver compared to other fat-soluble vitamins (Kayata et al., 1989). In
addition, poor diﬀusion of vitamin K across the placenta and only very
low concentrations of it within breast milk put newborns at risk for
vitamin K deﬁciency bleeding (VKDB), a rare and potentially dangerous
bleeding disorder in infants in the ﬁrst hours to months of life
(Anonymous, 1993; Kries et al., 1987; Sutor et al., 1999). As deﬁned by
the Paediatric Subcommittee of the International Society on Throm-
bosis and Haemostasis, VKDB can present itself in three forms: early,
classic, and late (Schulte et al., 2014). Early VKDB can present as an
intracranial haemorrhage during the ﬁrst 24 h of birth. This particular
form is most common in newborns whose mothers have been prescribed
antiepileptics, anticoagulants, or other medicines that interact and
prevent the normal functioning of vitamin K (Shearer, 2009). In con-
trast to early VKDB, the classic form of this condition is largely regarded
as idiopathic with the gastrointestinal tract, umbilical region, and skin,
which are deﬁned as common bleeding sites. These classic symptoms
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present themselves between the second and seventh day after birth
(Shearer, 2009). Late VKDB has been shown to mainly aﬀect breastfed
infants; however, there have been reports of links with hepatobiliary
dysfunction alongside other mild abnormalities of the liver (Matsuda
et al., 1989; Newman and Shearer, 1998; von Kries et al., 1985).
Bleeding due to this form of deﬁciency is present after the eighth day
and up to six months postbirth (Sutor et al., 1999).
Vitamin K prophylaxis can prevent VKDB (Schulte et al., 2014). The
World Health Organization recommends that newborns receive a 1mg
intramuscular (IM) injection of vitamin K at birth. Evidence from
multiple surveillance studies shows that the introduction of vitamin K
prophylaxis reduces the incidence of VKDB (Schulte et al., 2014).
Current recommendations support universal prophylaxis due to the lack
of predictors for vitamin K deﬁciency (Shearer, 2009). Despite these
recommendations, coverage of vitamin K prophylactic treatment in
low-resource settings is limited (Newman and Shearer, 1998).
Oral formulations are available, but the optimal regimen and asso-
ciated eﬃcacy of oral doses are not well understood. Both oral and IM
routes present disadvantages, which may aﬀect their eﬃcacy. Oral vi-
tamin K is administered as three 1mg doses at intervals of up to 5 weeks
(von Kries et al., 1995). Due to the short duration of action of each dose,
poor absorption in unknown liver abnormalities, and possible com-
pliance issues, infants may not be protected against late VKDB by oral
administration of vitamin K (Sutor et al., 1999). IM administration, on
the other hand, involves a single 1mg dose of vitamin K. This is due to
its ability to produce mean plasma levels of vitamin K 20,000 times
greater than normal levels, 4 h postinjection (McNinch, 2010; Shearer,
1995). Although eﬀective, a recent survey in a single southeastern state
in the United States highlighted the concerns and mindset of expectant
parents intending to refuse IM vitamin K prophylaxis (Hamrick et al.,
2016). Eighty-three per cent of parents in this study reported awareness
of the risks associated with vitamin K refusal; however, only 11%
decided to accept IM prophylaxis after discussions with study workers
(Hamrick et al., 2016). Reasons for refusal included concerns over in-
jection pain, localised bruising, and toxic ingredients (Hamrick et al.,
2016).
A novel delivery mechanism using drug-loaded dissolving micro-
needles (MNs) has been designed to provide a potential alternative to
hypodermic needles (Kaushik et al., 2001). MN arrays consist of mi-
cron-scale projections arranged in perpendicular orientation to a
baseplate. MNs can encapsulate drug within the baseplate or
throughout the entire array (González-Vázquez et al., 2017; McCrudden
et al., 2014). Dissolving MN arrays have been extensively used for the
delivery of a wide range of compounds, such as small molecules, pro-
teins and nanoparticles (Donnelly et al., 2012; González-Vázquez et al.,
2017; Kennedy et al., 2017; Larrañeta et al., 2016a, 2016b; Vora et al.,
2017). Upon application to the skin, interstitial ﬂuid causes the MN
polymer to dissolve, resulting in the release of the drug. This platform
has the ability to create microconduits through the stratum corneum,
enabling the delivery of drugs into the deeper regions of the skin where
they can be absorbed directly into the systemic circulation (Donnelly
et al., 2012).
There are signiﬁcant advantages in facilitating transdermal drug
delivery using MNs, one of which is self-application (Bariya et al., 2012;
Ripolin et al., 2017). As a result of a micron-scale design, penetration
does not reach the dermal layers, meaning application is pain-free
(Giudice and Campbell, 2006; Xie et al., 2005). Research has proven
that patients show no needle fear, discomfort is reduced, and healing is
faster at the injection site (Haq et al., 2009; Kaushik et al., 2001; Xie
et al., 2005). Furthermore, as this design of MN is dissolvable, it is
limited to one application; thus, it prevents needlestick injury and
eliminates sharps disposal requirements.
To date, dissolving MN arrays have been used to deliver hydrophilic
drug molecules such as theophylline, caﬀeine, and lidocaine (Garland
et al., 2012). On the other hand, hydrophobic, liquid drugs have yet to
be tested within an MN-based delivery platform. The objective of this
study was to incorporate vitamin K into a dissolving MN array for
neonatal prophylaxis of VKDB. This has the potential beneﬁt of im-
proving acceptance within developed countries and greatly reducing
VKDB cases in less economically developed countries (LEDCs).
2. Materials and methods
2.1. Chemicals
Gantrez® S-97, a copolymer of methyl vinyl ether and maleic acid,
was a gift from Ashland, Kidderminster, United Kingdom (UK). Tween®
80 and vitamin K1 (MW 450.71) were purchased from Tokyo Chemical
Industry UK Ltd., Oxford, UK. Polyvinylpyrrolidone (PVP; MW
40,000 Da) and hyaluronic acid (300 kDa) were purchased from Sigma-
Aldrich Company Ltd., Dorset, UK. All other chemicals used were of
analytical grade.
2.2. Manufacture of dissolving MN arrays
Vitamin K MNs were prepared by adding 2% w/w of vitamin K to
5% w/w Tween® 80, followed by gentle mixing. The appropriate vo-
lume of deionised water was then added and mixed to ensure disper-
sion. A 20% w/w aqueous blend of Gantrez® S-97 was prepared by
adding the correct mass to the vitamin K suspension, followed by
centrifugation at 2739g for 10min. Approximately 500mg of for-
mulation was poured into laser-engineered silicone micromolds, com-
posed of 121 (11× 11) conical holes, 600 µm in depth, with a base
width of 300 µm and interspacing of 300 µm. Each array was cen-
trifuged for 15min at 2739g, covered in aluminium foil, and allowed to
dry under ambient conditions for 48 h. After 48 h, MN arrays were
demoulded and sidewalls removed by a heated scalpel. The mass of
each MN array was recorded to determine vitamin K content.
2.3. Physical testing of MN arrays
Compression and insertion studies of vitamin K MN arrays were
tested using a TA.XT2 Texture Analyser (Stable Micro Systems Ltd.,
Haslemere, UK). Before compression, needle heights were visualised
and measured using a Leica EZ4W stereo microscope. Paraﬁlm M®
(Bemis Company Inc., Soignies, Belgium) was made into eight layers to
artiﬁcially simulate skin (Larrañeta et al., 2014). The MN arrays were
then inserted into the polymeric ﬁlm using the Texture Analyser, at a
speed of 1.19mm/s and force of 32 N, held for 30 s. Previous research
works determined that this is the average force applied by human vo-
lunteers in MN insertion experiments (Larrañeta et al., 2014; Lutton
et al., 2015). Needle height was measured as before to determine
compression, expressed as percentage height reduction. To quantify
insertion, each layer of Paraﬁlm M® was examined under the micro-
scope and the number of holes counted.
2.4. Fourier transform infrared spectroscopy analysis of vitamin K–loaded
MN arrays
Four scans (Tween® 80, vitamin K, 20% w/w Gantrez® S-97 with 5%
w/w Tween® 80 MN array, and a vitamin K–loaded MN array) were
performed using an FTIR (Fourier Transform Infrared Spectroscopy)
Accutrac FT/IR-4100 Series (Jasco, Essex, UK) equipped with Diamond
MIRacle™ ATR. To obtain each spectrum, an average of 64 scans were
recorded in the region of 4000–500 cm−1 at a resolution of 4.0 cm−1.
2.5. Determination of vitamin K recovery from MN arrays
Each vitamin K MN array was placed in 100% ethanol, covered in
aluminium foil, incubated at 37 °C, and agitated at 40 rpm. Once fully
dissolved, a sample was taken, diluted 100-fold, and assessed using
ultraviolet (UV) spectroscopy at wavelength 270 nm. This enabled drug
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content to be quantiﬁed, which was expressed in terms of percentage
drug recovery.
2.6. Humidity stability testing
The control for this test, relative humidity (RH) 43%, considered to
be bench-top humidity, was created using a saturated solution of po-
tassium carbonate (Greenspan, 1977). Comparison was made against
RH 86% by creating a saturated solution of potassium chloride
(Greenspan, 1977). Three MN arrays were placed into each environ-
ment, temperature controlled at 25 °C, and protected from light for
3 days. Physical characterisation and drug recovery were performed at
day 0 and day 3.
2.7. In vitro permeation studies
Vitamin K permeation through dermatomed (350 µm) neonatal
porcine skin (previously shown to be predictive of in vivo dissolving MN
performance25) was quantiﬁed using Franz diﬀusion cells. Skin was
shaved using a disposable razor and ﬁxed to the Franz cell donor
compartment using cyanoacrylate glue. Barrier integrity was conﬁrmed
using transepidermal water loss (Vapometer™, Delﬁn Technologies Ltd,
Kuopio, Finland) with the skin/donor compartment sitting atop the
ﬁlled receiver compartment. The skin/donor compartment set-up was
then placed on dental wax covered with aluminium foil to provide
support and to conﬁrm MN skin insertion. The MN array was placed in
the centre of the skin and gentle pressure applied for 30 s, with a 5.0 g
circular stainless steel weight then placed on top. Each receiver com-
partment was ﬁlled with PBS (pH 7.4), thermostatically maintained at
37 ± 1 °C. A metal stir bar was added to provide agitation (600 rpm)
before the donor compartment was placed on top and clamped into
place. To prevent losses to evaporation, Paraﬁlm M® was placed over
each Franz cell before occluding the sampling arm with Blu-Tack™
(Bostik Ltd, Leicester, UK). At each speciﬁed time point, 200 µL samples
were removed from the receiver compartment using 1mL syringes at-
tached to 8.0 cm needles and an equal volume of fresh pre-warmed PBS
added to replace this. To determine drug content, samples were ﬁltered,
diluted appropriately in 100% ethanol and vortexed for 10 s before UV
analysis.
2.8. Pharmaceutical analysis of vitamin K
Vitamin K was quantiﬁed using UV spectroscopy (Epoch Microplate
Spectrophotometer with Gen5 software, BioTek, Winooski, VT, USA).
Vitamin K has two absorption maxima (248 nm and 270 nm). However,
to reduce interference, the longer wavelength was used. Six con-
centrations were prepared by serial dilution from a 200 µg/mL stock
solution, using 100% ethanol as the solvent. Three 200 µL samples of
each solution were placed on an acrylic 96 well plate (Corning
Incorporated, Kennebunk, USA) prior to UV analysis. Samples con-
taining skin extracts were employed to conﬁrm lack of interference with
curve linearity.
Least squares linear regression analysis and correlation analysis
provided the coeﬃcient of determination (R2), line equation, and re-
sidual sum of squares for each calibration plot produced over three
consecutive days. Limit of detection (LoD) and limit of quantiﬁcation
(LoQ) were calculated using Eqs. (1) and (2), with S notating the slope









Accuracy and relative standard deviation were calculated from both
intraday and interday calibration plots to conﬁrm validity. Three vi-
tamin K concentrations (2.5, 5, and 20 µg/mL) within the linear range
were chosen for analysis.
2.9. Statistical analysis
Data were analysed, where appropriate using the Mann-Whitney U
test. In each case, p < 0.05 was considered to denote signiﬁcance.
Statistical analysis was performed using GraphPad Prism® version 5.0










Fig. 1. Light microscope images of vitamin K MN formulations. a) MN formulated from 20% w/w Gantrez® S-97 in 100% ethanol produced a large number of bubbles throughout the
array. b) MN formulated from 20% w/w PVP in 100% ethanol produced a brittle needle, although all the needles did form. c) MN formulated from 20% w/w PVP in deionised water,
containing 5% w/w Tween 80® produced a very brittle needle. Some needles did not form either. d) MN formulated from 20% w/w Gantrez® S-97 and 5% w/w Tween® 80 created a
strong array with fully formed needles.
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3. Results
3.1. Manufacture of dissolving vitamin K MN arrays
MN arrays were prepared using a variety of polymers and solvents
alone or in combination with Tween® 80 (Fig. 1). Hyaluronic acid–-
based MN formulation (not pictured) produced a very ﬂexible array
that was not capable of skin insertion. A dissolving MN formulation
based on 20% w/w Gantrez® S-97, 5% w/w Tween® 80, and 2% w/w
vitamin K produced fully formed, sharp needles with a strong baseplate.
These physical properties enabled further testing on this formulation.
Over the 48-h drying period, a mass loss of 69.6 ± 0.44% was
observed because of water evaporation. This increased the vitamin K
concentration to 13.2 ± 0.25% w/w. A further 74.3 ± 3.48% mass
loss was calculated due to removal of sidewalls. This resulted in an
average vitamin K content of 5.14 ± 0.70mg per array.
3.2. Mechanical and humidity stability testing of MN arrays
To investigate the eﬀects of compression, a TA.XT2 Texture
Analyser was used. This applied a 32 N uniform force to each MN array
for 30 s. This conditions were taken from previous works as they si-
mulate the average force applied by human volunteers when applying
MN arrays (Larrañeta et al., 2014; Lutton et al., 2015). Moreover, in a
previous work, Larrañeta et al. showed 11×11 MN arrays (600 µm
needle height) presented the maximum insertion for forces higher than
30 N. Consequently, the selected force of 32 N was the optimum force
for the mechanical testing of the array.
After compression on day 0, there was no signiﬁcant diﬀerence in
needle height following insertion into Paraﬁlm M® (p > 0.05). This
resulted in a mean height reduction of 7% as shown in Fig. 2a. An
estimation of skin depth penetration was assessed using eight layers of
Paraﬁlm M®. This insertion study was performed in conjunction with
compression analysis. On application of a 32 N force on day 0, more
than 20% of the needles penetrated the third layer and less than 20%
penetrated the fourth layer as shown in Fig. 2d. As described by Lar-
rañeta et al., penetration is regarded as successful if the number of holes
created in each layer is greater than 20% (Larrañeta et al., 2014).
Therefore, it can be assumed that the needles lie within the third and
fourth layers. Furthermore, as a single Paraﬁlm M® layer is approxi-
mately 126 µm thick, the insertion depth of each needle is in the range
of 378–504 µm.
Vitamin K MN arrays were subjected to RH 43% or RH 86% for
3 days to test the eﬀect of humidity on MN mechanical properties.
Mechanical properties were assessed as detailed previously to allow
comparison with MN characteristics on day 0. At RH 43%, there was no
signiﬁcant diﬀerence in needle height following compression
(p > 0.05). This resulted in a needle height reduction of 11% as shown
in Fig. 2b. At RH 86%, a height reduction of 5% was determined with
no signiﬁcant diﬀerence in needle height following compression
(p > 0.05). It was noted, however, that MN arrays at RH 43% were
brittle in contrast to RH 86%, which produced a softer, more ﬂexible
MN array. At RH 43%, insertion studies revealed less than 20% needle
penetration into the third layer of Paraﬁlm M®. This resulted in a pe-
netration depth of 252–378 µm. Less than 20% penetration was ob-
served in the fourth layer at RH 86%, showing a penetration depth of
378–504 µm. Although there was reduced needle penetration and
height at RH 43% compared to RH 86%, this was not statistically sig-
niﬁcant (p > 0.05).
3.3. Pharmaceutical analysis of vitamin K
Quantiﬁcation of vitamin K was determined using UV spectroscopy.
The wavelength used for UV analysis in this study was 270 nm.
Table 1 shows the calibration curve parameters for UV analysis of
vitamin K. Linearity of the calibration plot was observed in the range
0.625–20 µg/mL, conﬁrmed by an R2 value of 1. The equation of the
calibration plot was deﬁned as y=0.0178x− 0.0001, with LoD and
LoQ conﬁrmed as 0.031 µg/mL and 0.093 µg/mL respectively. Interday
and intraday variation was expressed in terms of relative standard de-
viation and accuracy. Three concentrations were chosen to represent
high, middle, and low vitamin K concentrations.
Illustrated in Table 2, interday and intraday accuracy was calculated
at 99.2%–99.6% and 99.6%–101.2% respectively, meaning this method
is accurate. Precision expresses the closeness of agreement between a
series of measurements obtained from multiple sampling of the same
sample under the same conditions. Relative standard deviation for both
intraday and interday analysis was found to be low, proving that this
method is precise and reproducible.
3.4. FTIR analysis of vitamin K–loaded MN arrays
FTIR analysis was performed to assess interactions between vitamin
K MN components (Fig. 3). As exploited in swellable MN arrays, there is
potential esteriﬁcation between Gantrez® S-97 acid groups and the
hydroxyl groups of Tween® 80 (Donnelly et al., 2014b). However, in
this case, no crosslinking occurred as MN fabrication was performed at
room temperature. This can be seen in the FTIR spectra as the Gantrez
carbonyl peak (1600–1700 cm−1) did not show any change (Fig. 4c &
d) (Larrañeta et al., 2018, 2015; Larraneta et al. 2018). Visual analysis
of each spectrum showed no shift in peaks, proving there are no in-
teractions between MN components.
3.5. Determination of vitamin K recovery from MN arrays
Day 0, RH 43% and RH 86% vitamin K MN arrays were recovered to
levels above 90% after 24 h in 100% ethanol. The average amount of
vitamin K recovered at day 0 was 90.3 ± 4.4%. After 3 days, a higher
percentage recovery was determined, with RH 43% and RH 86% pro-
ducing 96.3 ± 3.2% and 93.5 ± 4.6% respectively. Comparing these
results, there is no statistical diﬀerence between each condition in re-
lation to drug recovery (p > 0.05).
3.6. In vitro permeation studies
MN insertion into neonatal porcine skin was conﬁrmed before
proceeding to an in vitro delivery study. MN arrays were inserted into
full-thickness (1mm) porcine skin by applying constant ﬁnger pressure
for 30 s. Optical coherence tomography (OCT) using an EX1301 OCT
microscope (Michelson Diagnostics, Kent, UK) enabled visual assess-
ment of needle insertion. As shown in Fig. 4a, MN arrays had the ability
to bypass the stratum corneum and reach the dermal layers.
Vitamin K was detected in the Franz receiver compartment by UV
analysis after 15min. As illustrated in Fig. 4b, permeation of vitamin K
through neonatal porcine skin occurred throughout the 24-h experi-
ment, with MN arrays delivering 1.80 ± 0.08mg of vitamin K during
this period. As each MN array contains 5.14 ± 0.70mg of vitamin K,
approximately 35% of the contained drug was delivered across the
porcine skin in 24 h.
4. Discussion
Research in the ﬁeld of transdermal drug delivery has shown that
hydrophobic drugs do not possess the ideal characteristics for skin
permeation. A previous study by Lopes et al. highlighted this principle
by investigating the delivery of vitamin K using a monoolein-based
nanodispersion (Lopes et al., 2007). The results proved that topical
administration does not deliver the amount of vitamin K required to
alter systemic levels and aﬀect blood coagulation (Lopes et al., 2007).
This was due to its low penetration through the stratum corneum and the
viable epidermis (Lopes et al., 2007).
The data presented here represent the ﬁrst time vitamin K has been
A.R.J. Hutton et al. International Journal of Pharmaceutics 541 (2018) 56–63
59
delivered in vitro to a suﬃcient level using a dissolving MN array. The
delivery system presented in this study is designed to breach the stratum
corneum in a pain-free manner, such that the hydrophilic properties
required for passive diﬀusion through the skin are negated.
The ability to achieve a high concentration of vitamin K in the
plasma over a short time frame is exploited in IM delivery. Although an
injection using this route is reliable and eﬀective, the necessity for a
needle poses potentially serious health risks (Haq et al., 2009). In the
UK, there are reports of more than 100,000 needlestick injuries in
hospitals each year (Anonymous). Injuries of this nature are eﬀectively
undocumented in LEDCs; however, a lack of funding and health edu-
cation in LEDCs is widely believed to result in a greater annual number
Fig. 2. a) Compression analysis of vitamin K MN arrays, formulated from 20% w/w Gantrez® S-97 and 5% w/w Tween® 80, at day 0. Before compression, needle height was
0.517 ± 0.057mm (means ± SD, n=3). After a 32 N force was applied, needle height was 0.480 ± 0.072mm. b) Comparison of vitamin K MN arrays subjected to RH 43% or RH 86%
for 3 days. At RH 43%, before and after compression, needle height was 0.468 ± 0.065mm and 0.415 ± 0.103mm respectively (means ± SD, n=3). RH 86% resulted in needle
heights of 0.449 ± 0.093mm and 0.427 ± 0.086mm, before and after compression (means ± SD, n=3). c) Images of the ﬁrst 3 layers of Paraﬁlm M® used to measure insertion of a
vitamin K MN array at day 0. Layers 1 and 2 show 100% needle penetration, with 72% needle penetration through the third layer. d) Number of Paraﬁlm M® layers penetrated and
percentage holes created in each layer to enable calculation of mean insertion depth for 3 MN conditions.
Table 1
Calibration parameters for quantiﬁcation of Vitamin K using UV spectroscopy, as re-












Vitamin K 0.625–20 1 y= 0.0178x− 0.0001 0.031 0.093
Table 2
Determination of accuracy and precision for the quantiﬁcation of Vitamin K using UV spectroscopy in 100% ethanol.
Drug
Theoretical 






















Vitamin K 2.5 2.49 ± 0.03 1.2 99.6 2.48 ± 0.03 1.4 99.2
5 4.98 ±  0.03 0.5 99.6 4.98 ± 0.03 0.6 99.6
20 20.23 ± 0.48 2.4 101.2 19.99 ± 0.06 0.3 99.5
Intraday Interday 
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of injury and needle reuse cases than in developed countries (Anon-
ymous). An assessment by the World Health Organization states that
unsafe practice and needle reuse have contributed to 37.6% of hepatitis
B, 39% of hepatitis C, and 4.4% of HIV cases worldwide (Prüss-Üstün
et al., 2003). Furthermore, in LEDCs, poor disposal systems result in
needles residing in open dumps and vacant land, presenting signiﬁcant
danger to “rag scavengers” (Medina, 2010). It is estimated that, in
LEDCs, up to 2% of the population survive by scavenging (Medina,
2010). Consequently, unsafe disposal can result in needlestick injury to
these vulnerable members of society, hereby increasing the inherent
risk of cross-infection of bloodborne pathogens. In contrast, a dissolving
vitamin K MN only permits a once-oﬀ application, preventing reinser-
tion into a diﬀerent individual and eliminating sharps disposal re-
quirements and the risk of cross-contamination.
Dissolving MN arrays are composed of approximately 5%–10% w/w
water in the dried state. This presents issues with the incorporation of
vitamin K, a water-insoluble vitamin. Vitamin K is soluble in ethanol, so
initially this was the solvent used during MNmanufacture. This resulted
in a large number of bubbles throughout the MN array due to rapid
solvent evaporation. A polysorbate-based formulation using Tween® 80
was subsequently devised to aid the solubilisation of vitamin K in
water. As a surfactant, this produced a spherical micelle with a hy-
drophilic surface and hydrophobic core. Due to its hydrophobicity, vi-
tamin K concentrated within the core of Tween® 80. Several polymers
were considered. However, PVP-based MN arrays were too brittle and
hyaluronic acid MN arrays were too ﬂexible; neither were capable of
penetrating the stratum corneum. A formulation based on Gantrez® S-97
created a MN array with suﬃcient strength for insertion. IR analysis
was used to display no-component interactions within this formulation.
Compression analysis showed that needle height was only reduced by
11%, with all needles remaining intact on the baseplate. Insertion
studies using Paraﬁlm M® as an artiﬁcial skin model indicated that
these MN arrays can penetrate to a depth between 378 and 504 µm.
Following this, MN insertion into full-thickness porcine skin was con-
ﬁrmed using OCT imaging. In vitro skin permeation of vitamin K in-
creased over the course of the experiment with 1.80 ± 0.08mg of drug
released after 24 h. As mentioned previously, an IM injection delivers
1mg of vitamin K into each patient. Therefore, this study demonstrates
the potential of a 0.49 cm2 MN patch delivering a therapeutic dose of
vitamin K as prophylaxis for VKDB in newborn babies. The delivered
dose is equivalent to approximately 35% of drug permeating through
the skin. Although there was visible drug residue on the upper surface
of the neonatal porcine skin after 24 h, this could safely be removed and
disposed appropriately. Taking into account the hydrophobic nature of
vitamin K it is likely that a signiﬁcant amount of the drug was retained
within the SC. However, we believe that the drug wastage is not sig-
niﬁcant in this case considering all the advantages of the MN system
over conventional IM injections.
The dissolving nature of this MN array formulation will result in the
deposition of Gantrez® S-97 within the skin. Gantrez® S-97 is a non-
degradable polymer approved by the US Food and Drug Administration
with widespread use within the cosmetic and pharmaceutical industry;
however, its large molecular weight (1500 kDa) is above the threshold
for glomerular ﬁltration, which could result in polymer accumulation in
the tissue upon repeat administration (Donnelly et al., 2014a; Jones
et al., 2016; Quinn et al., 2016). Although Gantrez® S-97 polymer has
low toxicity, accumulation could result in erythema or granuloma for-
mation (Quinn et al., 2016). As mentioned previously, this MN array is
designed to administer a once-oﬀ dose of vitamin K. Therefore, it is
predicted that accumulation is unlikely to have any unfavourable ef-
fects on the health of neonates.
The eﬀects of humidity on vitamin K MN arrays were assessed by
exposing the MN arrays to RH according to ICH guidelines on stability
testing of new drug substances and products prior to compression and
Fig. 3. FTIR analysis showing a) Dissolving MN array containing 20% w/w Gantrez® S-97
and 5% w/w Tween® 80 formulated in deionised water. b) Tween® 80. c) Vitamin K. d)
Dissolving vitamin K MN array containing 20% w/w Gantrez® S-97, 5% w/w Tween® 80
and 5.14 ± 0.7 mg vitamin K.
Fig. 4. a) Optical coherence tomography image of a dissolving vitamin K MN array following manual insertion into neonatal porcine skin. b) In vitro cumulative permeation proﬁle of
vitamin K across dermatomed 350 µm neonatal porcine skin using a dissolving MN prepared from aqueous blends containing 20% w/w Gantrez® S-97 and 5% w/w Tween® 80 over 24 h
(means ± SD, n=3).
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insertion studies. These guidelines recommend stability testing proto-
cols for climatic Zone I, II, III, and IV to minimize diﬀerent storage
conditions of submission of a global dossier. An equal number of MN
arrays were subjected to RH 43% and RH 86% for 3 days. Mechanical
testing revealed that RH 43% produced a brittle array in contrast to a
more ﬂexible array produced at RH 86%. The brittle nature at RH 43%
could be a result of further water evaporation, in contrast to RH 86%, in
which water could be absorbed into the MN array, hereby increasing
the plasticising eﬀect. The data presented show that transport and
storage environments must be highly controlled to maintain the stabi-
lity of this formulation. Vitamin K is also degraded over time by UV
light; this must be considered throughout the development process.
With this in mind, future work will involve further stability studies
based on temperature and light intensity in addition to in vivo drug
release testing.
5. Conclusion
This study has demonstrated that it is possible to incorporate vi-
tamin K into a dissolving MN array. The formulation chosen enabled
successful drug delivery in vitro over 24 h. In vivo testing to assess safety
and pharmacokinetics in a rat animal model will now be performed
alongside further investigation into the stability and storage require-
ments of the formulation.
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